DEA's Telemedicine Special Registration Rule Just Moved to Final Rule Stage — Target Date November 2026

Back in July, I referred to DEA's 2026 rulemaking agenda as "downright skinny" — four active priorities, down from 28 as recently as Fall 2023 — and flagged the telemedicine special registration rule as the one item on that thin list actually worth watching. We noted the obvious pressure point: the current telemedicine prescribing flexibilities expire December 31, 2026, and DEA would either have to finalize the rule or extend the flexibilities again.

We now appear to have an answer, at least on paper. On August 14, 2026, OIRA published its Introduction to the 2026 Unified Agenda, and buried in the Department of Justice section is a one-line status change that matters a lot more than its brevity suggests: Special Registrations for Telemedicine and Limited State Telemedicine Registrations (RIN 1117-AB40) has moved from Proposed Rule Stage to Final Rule Stage. The corresponding reginfo.gov entry lists an expected final action date of November 2026.

What Actually Changed

If you've been following this rulemaking, the substance of the proposal hasn't changed — DEA is still working from the January 17, 2025 NPRM, which would create three tiers of special registration under the Ryan Haight Act's long-dormant special registration provision (21 U.S.C. § 831(h)):

Telemedicine Prescribing Registration — physicians and board-certified mid-level practitioners, Schedules III–V.

Advanced Telemedicine Prescribing Registration — specialists only (psychiatrists, hospice and palliative care physicians, pediatricians, neurologists), extending to Schedule II for vulnerable patients.

Telemedicine Platform Registration — for qualifying online platforms that facilitate prescribing between clinicians and patients.

Registrants would still need EPCS, PDMP checks (phased in by state), identity verification, encounter documentation, and annual reporting to DEA — on top of separate state telemedicine registrations and fees ($888 per Special Registration, $50–$888 per state depending on registrant type).

What's changed is the agency's posture. According to the current agenda entry, DEA is reviewing more than 6,400 public comments on the proposal and "considering various alternatives" as it drafts the final rule. That's the first time DEA has attached a concrete target date to this rulemaking since the process began back in 2023.

Why November 2026 Does Not Seem to be a Random Date

This lines up precisely with the timeline pressure we flagged in July. DEA and HHS extended the COVID-era telemedicine flexibilities a fourth time on December 31, 2025, pushing the sunset to December 31, 2026, and were explicit that the extension was meant to buy time to finish this exact rulemaking. A November 2026 final rule would land roughly six weeks ahead of that expiration — enough runway, presumably, for registrants to apply for special registrations before the temporary flexibilities disappear, but not much more than that.

Given the volume of comments still under review, don't assume November holds, and don't assume the substance survives untouched. DEA has slipped this rule's timeline before — the original NPRM took nearly two years to become a revised proposal, and it has already outlasted three prior temporary extensions.

I'll keep tracking this one. Given how much can still shift between now and a final rule — the platform registration requirements and PDMP phase-in provisions drew significant pushback in the comment record — I'd expect at least one more substantive update before December 31st.